ADDvise Group AB (FRA:Q3I)
€ 0.14 (0%) Market Cap: 98.83 Mil Enterprise Value: 196.27 Mil PE Ratio: 0 PB Ratio: 0.93 GF Score: 84/100

Q2 2025 ADDvise Group AB (publ) Earnings Call Transcript

Jul 17, 2025 / 12:00PM GMT
Release Date Price: €0.0983 (-16.41%)

Key Points

Positve
  • ADDvise Group AB (FRA:Q3I) reported a strong cash flow from operations at SEK70 million, a significant improvement from minus SEK19 million last year.
  • The company successfully finalized a new financing structure, reducing annual financing costs by approximately SEK56 million.
  • The Lab segment delivered a strong EBITA margin of 21%, indicating robust performance in this area.
  • ADDvise Group AB (FRA:Q3I) maintained a stable EBITA margin of 16%, slightly higher than last year's 15%, despite currency headwinds.
  • The company continues to focus on its acquisition strategy, aiming for sustainable value creation and potential EBITDA growth through strategic acquisitions.
Negative
  • The company experienced a year-over-year net sales decline of 4% when including FX effects.
  • There is softness in large CapEx-related sales cycles, indicating potential challenges in securing large projects.
  • The strengthening of the Swedish krone has negatively impacted top-line revenue and earnings through translation effects.
  • ADDvise Group AB (FRA:Q3I) is involved in a dispute regarding an earn-out claim amounting to approximately EUR6 million, which could impact financials.
  • The company's net debt leverage remains at 3 times EBITDA, which could limit flexibility in pursuing further acquisitions without addressing debt levels.
Operator

Welcome to ADDvise Group Q2 2025 report presentation. (Operator Instructions) Now I will hand the conference over to CEO, Staffan Torstensson; and CFO, Johan Irwe. Please go ahead.

Staffan Torstensson;publ;Chief Executive Officer
ADDvise Group AB;Director, Head of the Healthcare

()- -

Thank you, operator, and good afternoon, everyone. Our performance in the second quarter was in line with our expectations across revenue, earnings, and a bit stronger when it comes to cash flow. We saw a strong momentum in our lab equipment and clinical trials business, which helped offset the tough comparison to last year's Q2 when we benefited from several large clean room orders.

While the macroeconomics environment remains uncertain, with rising geopolitical tensions and a new tariff developments, the market we operate in are holding up relatively well. That said, we are seeing some softness in large CapEx-related sales cycles. We are also experiencing a headwind from the recent strengthening of the Swedish krone, which has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot